Stride immunotherapy shows long-term survival in advanced hepatocellular carcinoma

Long-term results from the phase 3 Himalaya study indicate that 14% of patients with advanced hepatocellular carcinoma treated with the Stride immunotherapy combination are alive after seven years. When including patients who achieved disease control, the survival rate rises to 20%, according to oncologist Lorenza Rimassa.

The Stride regimen consists of a combination of two immunotherapeutic drugs: tremelimumab, administered as a single initial dose, and durvalumab. This treatment was compared against sorafenib, a standard pharmacological therapy for advanced hepatocellular carcinoma. The study focused on patients with disease that was not treatable through direct procedures such as surgery or locoregional treatments.

Presented at the European Society for Medical Oncology (ESMO) congress, the data suggests that the benefits of the treatment, including disease control and survival, can be sustained over time. Rimassa noted that no new serious adverse events attributed to the therapy were observed in the seven-year analysis.